Drug Type Antibody toxin conjugate |
Synonyms Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein, DT-2219, DT-2219ARL + [6] |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Leukemia | Phase 2 | US | 21 Dec 2015 | |
B-cell lymphoma recurrent | Phase 2 | US | 21 Dec 2015 | |
B-cell lymphoma refractory | Phase 2 | US | 21 Dec 2015 | |
Leukemia | Phase 1 | US | 02 Dec 2013 | |
Lymphoma | Phase 1 | US | 02 Dec 2013 |
Phase 1/2 | 18 | fuqpenyjet(xbakalmzci) = xrybcysedj ivgcvnpvmt (wmpbxejahe, ciiqvsfkiw - wgcpiejcwh) View more | - | 13 Jan 2020 | |||
Phase 1 | 25 | pjpcnhxoyu(axzftvxvyc) = including weight gain, low albumin, transaminitis, and fever were transient grade 1-2 and occurred in patients in higher dose cohorts (≥40 μg/kg/day) xttsplafhb (mgocvhkmqi ) View more | Positive | 15 Mar 2015 |